190 related articles for article (PubMed ID: 23098121)
1. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Chmielowski B; Federman N; Tap WD
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1217-28. PubMed ID: 23098121
[TBL] [Abstract][Full Text] [Related]
2. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
3. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
5. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
6. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Dancey JE; Monzon J
Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
8. Emerging agents for the treatment of mantle cell lymphoma.
Camara-Clayette V; Hermine O; Ribrag V
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1205-15. PubMed ID: 23098120
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
[TBL] [Abstract][Full Text] [Related]
12. New therapies in soft tissue sarcoma.
Vincenzi B; Frezza AM; Santini D; Tonini G
Expert Opin Emerg Drugs; 2010 Jun; 15(2):237-48. PubMed ID: 20465449
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.
Mohindra N; Agulnik M
Expert Opin Investig Drugs; 2015; 24(11):1409-18. PubMed ID: 26289790
[TBL] [Abstract][Full Text] [Related]
17. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).
Ronellenfitsch U; Dimitrakopoulou-Strauss A; Jakob J; Kasper B; Nowak K; Pilz LR; Attenberger U; Gaiser T; Egerer G; Fröhling S; Derigs HG; Schwarzbach M; Hohenberger P
BMJ Open; 2016 Jan; 6(1):e009558. PubMed ID: 26739732
[TBL] [Abstract][Full Text] [Related]
18. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
19. Other endpoints in screening studies for soft tissue sarcomas.
Verweij J
Oncologist; 2008; 13 Suppl 2():27-31. PubMed ID: 18434636
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
